uBriGene
Address: 421- 3800 Wesbrook Mall, Vancouver, British Columbia. V6S 2L9About Us
uBriGene Biosciences Inc. has established the integrated innovative CGT CDMO platforms that provide GMP-grade plasmid and T cell production services for large-scale CAR-T productions. We provide viral vectors, including adenovirus and lentivirus vectors to meet the demands of research and/or manufacturing applications. We are committed to driving innovation and accelerating cell and gene therapy development from target to market. With its fermentation capacity ranging from 5L to 500L, uBriGene offers a versatile selection of research grade, GMP-ready or GMP grade plasmids for research and clinical applications respectively. Our two-step purification technology allows fast and cost-effective cell harvesting process. uBriGene currently operates two state-of-the-art GMP facilities, including 21 clean suites with a total area of over 133,000 sq ft, and has produced 65 batches of GMP plasmids as of 2021. Since its founding, uBriGene has been providing one-stop service to fulfill comprehensive objectives of our clients, including some of the most cutting-edge leaders of the cell and gene therapy industry. We ensure the highest quality of products and services while striving to optimize for time and cost efficiency.
Sectors
- Contract Research & Development
- Contract Manufacturing
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
Categories
- Biologics
- Biotechnology
- Cell Therapy
- Cell Therapy Products
- Plasmid DNA
- Viral Vectors
- Viral Vectors- Adeno-Associated Viruses (AAV)
- Viral Vectors-Lentiviral Vectors (LVV)
- Cell Banking
- T-Cells
- CAR-T Therapies
- Tumour Targeting
- Stem Cells
- Exosomes
- Bioprocess Development
- Analytical Method Development & Validation
News
uBriGene Cellinfinity In Vivo CAR-T Partnership
Germantown, MD - March 30, 2026 - uBriGene Biosciences (uBriGene), a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing in vivo CAR-T therapies targeting hematologic and solid tumors.
This strategic partnership will accelerate the clinical advancement of Cellinfinity BIO’s therapeutic programs CIB-301 and CIB-350. uBriGene will leverage its high-productivity LVV Turbo™ platform to deliver efficient, cost-effective GMP lentiviral vector manufacturing, including process development, GMP production, and regulatory support.
uBriGene Acquires Mustang Bio’s GMP Manufacturing Facility
Location will produce cell and gene therapies and provide contract analytical services.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com